Alurol - Allopurinol | VetSafeCare.Com

Tab.

Alurol

Allopurinol — Incepta Pharmaceuticals Ltd.
100mg / tablet

Alternatives

8

Routes

PO

Presentations

1

Generic profile Browse alternatives View combinations

Presentations

Tablet · 100mg / tablet

1 tablet

৳4

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Dog

For urate uroliths:
a) For dissolution: 15 mg/kg PO q12h; only in conjunction with low purine foods.
For prevention: 10–20 mg/kg/day; because prolonged high doses of allopurinol may result in xanthine uroliths, it may be preferable to minimize recurrence with dietary therapy, with the option of treating infrequent episodes of urate urolith formation with dissolution protocols. (Osborne et al. 2003)
b) 7–10 mg/kg PO three times daily for both dissolution and prevention. Goal is to reduce urine urate:creatinine ratio by 50%. (Senior 1989)
For Leishmaniasis:
a) First line treatment: Meglumine antimoniate (N-methylglucamine antimoniate) 75 - 100 mg/kg once daily for 4-8 weeks plus allopurinol 10 mg/kg PO twice daily for 6-12 months. 

Second line treatment: Miltofosine 2 mg/kg PO once daily for 4 weeks plus allopurinol 10 mg/kg PO twice daily for 6-12 months OR allopurinol alone at 10 mg/kg PO twice daily for 6-12 months. (Solano-Gallego et al. 2009)
b) Meglumine antimoniate (100 mg/kg/day SQ) until resolution, with allopurinol at 20 mg/kg PO q12h for 9 months.
An alternate protocol using allopurinol alone: allopurinol 10 mg/kg PO q8h or 10–20 mg/kg PO q12h for 1–4 months. (Brosey 2005)
c) If possible use with meglumine antimoniate, if not, use allopurinol alone at 10 mg/kg PO twice daily. If animal has renal insufficiency, use at 5 mg/kg PO twice daily. (Font 1999)
d) 15 mg/kg PO twice daily for months (Lappin 2000)

Human

Adults: Allopurinol should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor. The following dosage schedules are suggested: 100 to 200 mg daily in mild conditions, 300 to 600 mg daily in moderately severe conditions, 700 to 900 mg daily in severe conditions.Children: Children under 15 years: 10 to 20 mg/kg body weight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.Elderly: In the absence of specific data, the lowest dosage which produces satisfactory urate reduction should be used.Dosage in renal impairment: In severe renal insufficiency, it may be advisable to use less than 100 mg per day or to use single doses of 100mg at longer intervals than one day.

Reptiles (Large)

a) For elevated uric acid levels in renal disease in lizards: 20 mg/kg PO once daily (de la Navarre 2003)
b) For gout: 20 mg/kg PO once daily. Suggested dosage based upon human data as dose is not established for reptiles. (Johnson-Delaney
2005)
c) For hyperuricemia in green iguanas: 25 mg/kg PO daily. (Hernandez- Divers et al. 2008)

Poultry / Birds

For gout:

a) Poultry: 25mg/kg body weight

 b) In budgies and cockatiels: Crush one 100 mg tablet into 10 mL of
water. Add 20 drops of this solution to one ounce of drinking water.

c) For parakeets: Crush one 100 mg tablet into 10 mL of water. Add 20
drops of this solution to one ounce of drinking water or give 1 drop 4
times daily.

Clinical notes

Applications:

N/A

Indication Notes:
Allopurinol is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis). Allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity ... Read moreAllopurinol is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis). Allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phospho ribosyltransferase. Allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.
Avoid In:

N/A

Contraindication Notes:
Allopurinol tablet is contra-indicated in patients with known hypersensitive to allopurinol.
Allopurinol is a xanthine oxidase inhibitor which is administered orally. It acts on purine catabolism without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. Allopurinol is a structural analogue of the natural purine base, hypoxanthine. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, the end product of purine metabolism. Allopurinol is approximately 90% absorbed from the GI tract. Peak plasma levels generally occur at 1.5 hours to 4.5 hours. It has a plasma half life of about 1 to 2 hours. Approximately 20% of the ingested Allopurinol is excreted in the faeces.
When 6-mercaptopurine or azathioprine is given concurrently with Allopurinol, only one-quarter of the usual dose of 6- mercaptopurine or azathioprine should be given because inhibition of xanthine oxidase will prolong their activity. Evidence suggests that the plasma half-life of vidarabine is increased in the presence of allopurinol. When the two products are used concomitantly extra vigilance is necessary, to recognise enhanced toxic effects. Theophylline levels should be monitored in patients starting or increasing allopurinol therapy. An increase in frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs. Reports suggest that the plasma concentration of ciclosporin may be increased during concomitant treatment with allopurinol.
Rashes, gastro intestinal disorder’s, rearly malaise, headache, vertigo, drowsiness, visual and test disturbances, hypertension, alopecia, hepatotoxicity, neuropathy, gynaeconastia and blood disorders.
Ingestion of up to 22.5 g allopurinol without adverse effect has been reported. Symptoms and signs including nausea, vomiting, diarrhoea and dizziness have been reported in a patient who ingested 20 gm allopurinol. Adequate hydration to maintain optimum diuresis facilitates excretion of allopurinol and its metabolites. If considered necessary haemodialysis may be used.
There is inadequate evidence of safety of Allopurinol in human pregnancy. Use in pregnancy only when there is no safer alternative and when the disease itself carries risk for the mother or unborn child. There are no data concerning the effects of allopurinol or its metabolites on the breast-feed baby.
Allopurinol should be withdrawn immediately when a skin rash or other evidence of sensitivity occurs. Reduced doses should be used in patients with hepatic or renal impairment. Patients under treatment for hypertension or cardiac insufficiency may have some concomitant impairment of renal function and allopurinol should be used with care in this group.